Delivering a mature banking and distribution operation

The ability of EBiSC to bank and distribute cell lines to satisfy user requests will be underpinned by the project reaching a number of key milestones as the operations are put in place.

The first project phase successfully established routine and robust procedures for collecting, banking, characterising and distributing EBiSC iPSC lines. The collaboration of iPSC research projects and deposit of established, authentic iPSC lines made from normal consenting donors, were pivotal in validating many of these standard procedures.

A gap analysis to assess what is existing and accessible and what is needed currently by users has identified new opportunities for EBiSC. Proactively broadening the EBiSC Collection to include many new disease representative and gene-edited lines for research and the provision of differentiated cell products and iPSC services will represent major distinctive features for the EBiSC catalogue.

The following five key components will come together in support of the development of mature banking and distribution activities.

  1. The design and implementation of bioengineering and quality control testing technologies will lead to eventual cost reductions, while increasing operational scale.
  2. Users will access far greater data than provided by other cell banks, on individual iPSC lines in the catalogue via the bespoke information management system. 
  3. Harmonisation of standards, policies, procedures and legal instruments, based on increased understanding of stakeholder interests and user needs will be implemented.
  4. Finally the strategic trajectory of the EBiSC banking and distribution operation will be mapped out in preparation for reaching self-sustainability. This will include a plan as to how it will collaborate with other iPSC global projects based on overlapping interests and also identify unique EBiSC propositions. 

Overall these components will be integral to mainstream EBiSC operations so that before the end of the project EBiSC2 will have demonstrated the capacity to operate a sustainable and
mature operation for which all of the major infrastructure and related technology development will have been completed.

Biobank © Fraunhofer IBMT, Photo: Bernd Müller